Market Place
Sourcing Support
Algernon Announces Warrant Extension
04 Nov 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Closing of Private Placement
20 Aug 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Increase to Private Placement
13 Aug 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Private Placement
07 Aug 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Closing of Private Placement
02 Aug 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Increase to Private Placement
31 Jul 2024 //
GLOBENEWSWIRE
Algernon Reports 93% Cough Suppression With Ifenprodil
16 Jul 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Private Placement
11 Jul 2024 //
GLOBENEWSWIRE
Algernon Engages ICP For Automated Market Making
21 May 2024 //
GLOBENEWSWIRE
Algernon, CHDR Present DMT Stroke Data in June
24 Apr 2024 //
GLOBENEWSWIRE
Algernon CEO Featured On Radius Webinar 4/16
11 Apr 2024 //
GLOBENEWSWIRE
Algernon to Move Forward with Psychedelic Drug DMT Stroke Research Program
01 Apr 2024 //
GLOBENEWSWIRE
Algernon Announces Closing of the Acquisition of its Chronic Cough Program
27 Mar 2024 //
GLOBENEWSWIRE
Algernon Receives Notice of Intention to Grant for Repirinast
31 Jan 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent
11 Jan 2024 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Increase to Private Placement
27 Dec 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Closing of Private Placement
27 Dec 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Private Placement
12 Dec 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Receives Notice of Intention to Grant for Repirinast
30 Nov 2023 //
GLOBENEWSWIRE
Algernon Announces LOI for Acquisition of its Chronic Cough Research Program
22 Nov 2023 //
GLOBENEWSWIRE
Algernon Pharma Receives Japanese Patent Notice of Allowance for Repirinast
08 Nov 2023 //
GLOBENEWSWIRE
Algernon Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
06 Sep 2023 //
GLOBENEWSWIRE
Algernon Neuro Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
08 Aug 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares
14 Jul 2023 //
GLOBENEWSWIRE
Algernon Engages Maxim Group to Explore Spin-Off of its Ifenprodil Ph 2 CCDDP
27 Jun 2023 //
GLOBENEWSWIRE
Algernon to Present Phase 2 Ifenprodil Cough Data at Conference
06 Jun 2023 //
GLOBENEWSWIRE
Algernon Announces Successful Completion of Single Dose in DMT Phase 1 Trial
05 Jun 2023 //
GLOBENEWSWIRE
Algernon Receives Notice of Allowance from the Japanese Patent Office
31 May 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Closing of Rights Offering
05 May 2023 //
GLOBENEWSWIRE
Algernon Reminds Shareholders of Previously Announced Rights Offering
20 Apr 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Notice of Allowance for Method
17 Apr 2023 //
GLOBENEWSWIRE
Algernon Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Study
04 Apr 2023 //
GLOBENEWSWIRE
Algernon Announces SEC Qualification of Regulation A+ Tier II Offering to Raise
03 Apr 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Launch of Rights Offering
21 Mar 2023 //
GLOBENEWSWIRE
Algernon NeuroScience Appoints Dr. David Brody to Advisory Board
02 Mar 2023 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split
28 Feb 2023 //
GLOBENEWSWIRE
Algernon Initiates Traumatic Brain Injury Research Program With DMT
21 Feb 2023 //
GLOBENEWSWIRE
Algernon Provides Update on Phase 1 DMT Clinical Study
16 Feb 2023 //
GLOBENEWSWIRE
Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
17 Jan 2023 //
GLOBENEWSWIRE
Algernon Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
11 Jan 2023 //
GLOBENEWSWIRE
Algernon to begin chronic cough therapy trial in third quarter of 2023
10 Jan 2023 //
CLINICALTRIALSARENA
Algernon Announces Plans for 180 Patient Ph 2b Chronic Cough Study of Ifenprodil
09 Jan 2023 //
GLOBENEWSWIRE
Algernon Pharma Forms Private Subsidiary to Advance Company’
03 Jan 2023 //
GLOBENEWSWIRE
Algernon Receives U.S. FDA Orphan Drug Designation for Ifenprodil
05 Dec 2022 //
GLOBENEWSWIRE
FDA grants orphan drug designation to Algernon`s ifenprodil, exclusivity unclear
05 Dec 2022 //
ENDPTS
Algernon begins screening of first subject in phase 1 DMT human stroke study
18 Nov 2022 //
PHARMABIZ
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
16 Nov 2022 //
GLOBENEWSWIRE
Algernon Enters into Agreement with Yale University for DMT PII Depression Study
24 Oct 2022 //
GLOBENEWSWIRE
Algernon Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” CEO
14 Oct 2022 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund f
21 Sep 2022 //
GLOBENEWSWIRE
Algernon Files for Orphan Designation with the U.S. FDA for Ifenprodil
19 Sep 2022 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT
12 Sep 2022 //
GLOBENEWSWIRE
Algernon Reports +ve Results from Full Data Set of its Ph2 Study of Ifenprodil
01 Sep 2022 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Announces Closing of Private Placement
23 Aug 2022 //
GLOBENEWSWIRE
Algernon Shareholder AlphaNorth Asset Management Increases Ownership Position
23 Aug 2022 //
GLOBENEWSWIRE
Algernon Pharma Invited to Present Phase 2 IPF and Chronic Cough Study Data
03 Aug 2022 //
GLOBENEWSWIRE
Algernon Pharma Reports Additional Positive Data From PII Study of Ifenprodil
28 Jul 2022 //
GLOBENEWSWIRE
Algernon Pharma Hits Co-Primary Endpoint in PII Study of Ifenprodil for IPF
19 Jul 2022 //
GLOBENEWSWIRE
Algernon Provides Update on Planned PI Repirinast Chronic Kidney Disease Study
11 Jul 2022 //
GLOBENEWSWIRE
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
07 Jul 2022 //
GLOBENEWSWIRE
